Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).

Thomas Benfield,Mika Rämet,Piero Valentini,Ilkka Seppä,Ron Dagan,Peter Richmond, Swati Mercer,Clay Churchill,Robert Lupinacci,Richard McFetridge, Jun Park,Frederick Wittke,Natalie Banniettis,Luwy Musey,Kara Bickham,Janusz Kaminski

Vaccine（2023）

引用 1|浏览15

暂无评分

摘要

A two-dose primary series plus toddler dose of V114 was well-tolerated in healthy infants. Compared with PCV13, V114 provided non-inferior immune responses to 13 shared serotypes and superior immune responses to additional serotypes 22F and 33F.

查看译文

关键词

Child,Clinical trial,Infant,Pneumococcal infections,Pneumococcal vaccines

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要